Cassava Sciences | PTIE - Pre Tax Profit


Cassava Sciences reported $-10.81M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Abbott USD 2.36B 178M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Cassava Sciences USD -10.81M 33.41M Sep/2025
Eisai JPY 22B 7.47B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Geron USD -31.14M 12.72M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Novartis USD 4.64B 445M Dec/2025
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025